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ABSTRACT  29 
Introduction 30 
Non-invasive ventilation (NIV) improves survival among patients with hypercapnic respiratory 31 
failure in hospital but evidence for its use in domiciliary settings is limited. A patient’s 32 
underlying risk of having an exacerbation may affect any potential benefit that can be gained 33 
from domiciliary NIV. This is the first comprehensive systematic review to stratify patients 34 
based on a proxy for exacerbation risk: patients in a stable state and those immediately 35 
post-exacerbation hospitalization. 36 
 37 
Methods 38 
Systematic review of randomized (RCTs) and non-randomized controlled trials comparing 39 
the relative effectiveness of different types of NIV with each other and usual care on hospital 40 
admissions, mortality and health-related quality of life (HRQoL). Standard systematic review 41 
methods were used for identifying studies (to September 2014), quality appraisal and 42 
synthesis. Data were presented in Forest plots and pooled where appropriate using random-43 
effects meta-analysis.  44 
 45 
Results 46 
31 studies were included. For stable patients there was no evidence of a survival benefit 47 
from NIV (RR 0.88 (0.55, 1.43), I2=60.4%, n=7 RCTs), but there was a possible trend 48 
towards fewer hospitalisations (WMD -0.46 (-1.02, 0.09), I2=59.2%, n=5 RCTs) and 49 
improved HRQoL. For post-hospital patients, survival benefit could not be demonstrated 50 
within the 3 RCTs (RR 0.89 (0.53, 1.49), I2=25.1%) although there was evidence of benefit 51 
from 4 non-RCTs (RR 0.45 (0.32, 0.65), I2=0%). Effects on hospitalizations were 52 
inconsistent. Post-hoc analyses suggested that NIV-related improvements in hypercapnia 53 
were associated with reduced hospital admissions across both populations. Little data were 54 
available comparing different types of NIV. 55 
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 56 
Conclusion 57 
The effectiveness of domiciliary NIV remains uncertain, however some patients may benefit. 58 
Further research is required to identify these patients and to explore the relevance of 59 
improvements in hypercapnia in influencing clinical outcomes. Optimum time-points for 60 
commencing domiciliary NIV and equipment settings need to be established. 61 
 62 
 63 
  64 
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INTRODUCTION 65 
     Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease, 66 
characterized by non-reversible airflow obstruction and intermittent exacerbations.1 67 
Treatment for COPD is based on pharmacotherapy, pulmonary rehabilitation and, in some 68 
cases, long-term oxygen therapy (LTOT). Exacerbations are a key cause of increased 69 
morbidity, mortality and poor health status, and place a considerable burden on the 70 
healthcare system.2 Approximately 15% of COPD patients per year have exacerbations 71 
necessitating hospital admission; 3;4 between 10-25% of patients admitted with hypercapnic 72 
respiratory failure due to COPD die in hospital.5 Reduced exacerbation frequency is 73 
therefore an important therapeutic target. 74 
 75 
     Non-invasive ventilation (NIV) is a method of providing ventilatory support via a mask and 76 
is effective in improving survival among patients with acute or acute-on-chronic hypercapnic 77 
respiratory failure in hospital6;7. Evidence for  domiciliary use of NIV in non-acute COPD 78 
patients is more limited despite a number of systematic reviews.8-11 As patients immediately 79 
post-hospitalization are at greater risk of recurrence of exacerbation than those more 80 
stable12, this difference could influence the effectiveness of NIV in preventing or reducing the 81 
impact of these events. This is the first systematic review to stratify data by these two patient 82 
groups and it is the most comprehensive review to date, including evidence from RCTs, non-83 
randomized controlled studies and RCTs comparing different NIV settings, and considering 84 
mortality, hospitalizations and quality of life (QOL) as outcomes. Finally, this is the first 85 
systematic review to attempt an analysis, albeit exploratory, of the relationship between 86 
hypercapnia and clinical outcomes. 87 
 88 
METHODS 89 
A protocol detailing the methodology was registered with PROSPERO 90 
(CRD42012003286).13;14 A summary of the methods is presented here. Search strategies 91 
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incorporated a combination of text words and index terms relating to NIV and COPD. 92 
Bibliographic databases (MEDLINE, MEDLINE In Process, EMBASE, Cochrane CENTRAL, 93 
CINAHL and Science Citation Index Expanded (ISI)), the British Library’s ZETOC and ISI 94 
Conference Proceedings Citation Index (CPCI) and clinical trials registers were searched 95 
from 1980 to Sept 2014. No study design or language restrictions were imposed. Citation 96 
checking of included studies was undertaken, and experts in the field consulted to identify 97 
further studies. The search strategy for MEDLINE is shown in the supplementary file. 98 
 99 
Studies were eligible for inclusion if they met the criteria shown in Table 1.  100 
Primary outcomes of interest were mortality, hospitalizations, exacerbations and QOL. 101 
Secondary outcomes included lung function and blood gases. Study selection was 102 
performed by two reviewers independently. Disagreements were resolved through 103 
discussion and/or referral to a third reviewer. 104 
 105 
Risk of bias was assessed based on the Cochrane collaboration risk of bias tool (for RCTs 106 
and non-randomized controlled studies), with additional criteria considered for crossover 107 
trials (ie whether there was a carry-over effect; whether only first period data were available; 108 
whether analysis was appropriate to cross-over trials; and comparability of results with those 109 
from parallel-group trials).15  110 
 111 
Data extraction was performed by one reviewer using a standardized, piloted data extraction 112 
form, with numerical data checked by a second reviewer. Study selection and data extraction 113 
of non-English language papers was performed by native speakers of the respective 114 
languages with guidance from the reviewers.  115 
 116 
Studies were grouped according to average proximity of patients to their most recent 117 
exacerbation that required hospitalization. If patients had not been hospitalized within 4 118 
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weeks to 3 months at commencement of the study or were described as “stable”, they were 119 
classed as the stable population. Where there was clear evidence that treatment with NIV in 120 
a study commenced after an episode of hospitalization (due to an exacerbation), these 121 
patients were classed as the post-hospital population, with the assumption that on average 122 
this population were at greater risk of a subsequent exacerbation.  123 
 124 
Separate analyses were performed for each study design (RCT, controlled studies) and 125 
primary outcome (survival and hospitalizations). Where there was clinical and 126 
methodological homogeneity between studies reporting the same outcome and using the 127 
same outcome statistic (reported or calculable), random effects meta-analysis was 128 
undertaken in STATA (Stata Statistical Software: Release 10. StataCorp LP). Results for 129 
other primary outcomes were reported narratively (exacerbations and QOL). Secondary 130 
outcome data (FEV1, FVC, PaCO2, PaO2, 6MWD) were not pooled due to between study 131 
heterogeneity, but is presented in forest plots in order to show the overall direction of effect 132 
and uncertainty. 133 
 134 
Exploratory post-hoc analyses of study level data were performed to determine if baseline 135 
hypercapnia could predict response to NIV, or whether change in hypercapnia correlated 136 
with any effect of NIV on mortality and hospitalizations.  137 
 138 
PRISMA reporting guidelines are adhered to.16 139 
 140 
RESULTS 141 
Main study characteristics 142 
Screening of the 7,405 records identified by the searches yielded 21 RCTs (18 NIV v usual 143 
care; 3 NIV vs another form of NIV) and 10 non-randomized controlled studies (5 144 
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prospective, 5 non-prospective; Figure 1). Table 2 shows the main characteristics of these 145 
studies.  146 
All patients had GOLD stage III and/or IV COPD, or were described as ‘severe’ (where 147 
reported). Eighteen studies provided details on assessing patients for obstructive sleep 148 
apnea, to rule out overlap syndrome. Twenty studies were in stable populations, 9 in post-149 
hospital populations and there were no details for two. For post-hospital populations there 150 
was clear evidence in all study reports that NIV treatment commenced after hospitalization 151 
due to an exacerbation. For both populations there was usually no information on the length 152 
of time before NIV was initiated, or previous exacerbation history. Varying proportions of 153 
patients were on LTOT. Most studies included hypercapnic patients, though the cut-off for 154 
classification varied. Two RCTs17;18 included normocapnic patients, whilst one RCT19 stated 155 
that the number of hypercapnic patients included was small. 156 
 157 
NIV settings, therapeutic/tolerability targets (pressure, volume or blood gases), and reporting 158 
of these varied across studies. There was some variability in usual care, with three studies 159 
considered to have more intensive approach to usual care: a 12-week multidisciplinary 160 
rehabilitation program, followed by a long-term home-based rehabilitation program20;21; a 161 
pulmonary rehabilitation program for part of the RCT18 and a "home supervision program"22.  162 
 163 
There was a lack of reporting of some details relevant to study quality, particularly regarding 164 
loss to follow-up, handling of missing data and blinding of outcome assessors. Only three 165 
RCTs included a “sham NIV” arm, lack of which may have led to performance bias and/or 166 
bias in patient reported QOL. By definition, the non-randomized studies were more prone to 167 
bias; some retrospective studies had clear evidence of baseline imbalances between NIV 168 
and comparator groups, with the consequence of this on study findings unknown.  169 
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Length of follow-up varied between 3 and 24 months (RCTs) and between 12 months and 10 170 
years (controlled studies). The longest follow-up periods (4-10 years) were in the 171 
retrospective controlled studies.  172 
Main findings  173 
NIV compared with usual care only: stable population 174 
Data from 7 RCTs19;21;23-27 (pooled RR 0.88 (0.55, 1.43), I2=60.4%) and 4 controlled 175 
studies22;28-30 (pooled RR 1.19 (0.65, 2.18), I2=0%) suggested no significant difference 176 
between domiciliary NIV and usual care alone in terms of survival up to 24 months (Figure 177 
2). Excluding the RCT by Casanova19, which included only few patients with hypercapnia, 178 
had little effect, changing the pooled RR to 0.85 (0.46, 1.58). Data from 5 RCTs21;23-25;27 and 179 
3 controlled studies22;28;29 (Figure 3) suggested a  trend towards fewer hospital 180 
admissions/days in hospital with NIV, , albeit not statistically significant. Evidence on 181 
exacerbations not leading to hospitalization based on 4 RCTs17;19;21;24 and one controlled 182 
study29  showed no significant effect of NIV (supplementary file). For QOL, there appeared to 183 
be a trend favoring NIV, but a consistent benefit could not be demonstrated; heterogeneity in 184 
outcomes measured and time-points hampered analyses of this measure (supplementary file 185 
). There was some evidence to suggest NIV improved blood gases (based on mainly 186 
unadjusted results; Figure 4 and 5).  187 
 188 
NIV compared with usual care only: post-hospital population 189 
No survival benefit was evident from  three RCTs31-33 (pooled RR 0.89 (0l.53, 1.49), I2= 190 
25.1%), though four non-randomized controlled studies34-37, which are potentially more prone 191 
to bias, favored NIV (pooled RR 0.45 (0.32, 0.65), I2=0%; Figure 2). Findings for hospital 192 
admissions were inconsistent, with one RCT33 finding a statistically significant benefit of NIV, 193 
one31 marginally favoring NIV and one32 marginally favoring usual care (without NIV) (Figure 194 
3). Quality-of-life data was reported in only one post-hospital RCT32, and there were no 195 
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differences between NIV and usual care. Limited data  from three trials31-33 suggested a 196 
potential benefit from NIV in terms of reduction in PaCO2 (Figure 5). 197 
 198 
Study quality 199 
None of the RCTs assessed as having a high risk of bias contributed data to meta-analyses, 200 
yet some of the non-randomized controlled studies in the meta-analyses (for both 201 
populations) did. The small number of studies precluded assessment of the potential for 202 
publication bias (eg using funnel plots) and sensitivity analyses around study quality.  203 
 204 
Sub-group analysis 205 
No further sub-group analysis (beyond study design and population) was possible given the 206 
small number of trials and inconsistent reporting of relevant characteristics. However, many 207 
clinicians believe the extent of hypercapnia or a change in hypercapnia status are related to 208 
the effect of NIV. In this context it is worth noting that the study by Köhnlein (2014)23 had the 209 
highest hypercapnia threshold as an eligibility criterion (PaCO2 ≥7kPa), and also showed a 210 
statistically significant survival benefit (and a non-significant trend towards fewer hospital 211 
admissions). Further, the study by Zhou (2008)24, which along with the Köhnlein (2014)23 212 
study had the highest mean PaCO2 found a statistically significant benefit from NIV in 213 
hospital admissions. In order to explore hypercapnia level further as a potential predictor of 214 
benefit from NIV, data on mean PaCO2 levels prior to initiation of NIV and change in mean 215 
PaCO2 levels due to NIV from each study (where reported) were plotted against mortality 216 
and hospitalization data in order to determine if baseline PaCO2 levels could predict 217 
response to NIV, and whether the effect of NIV on PaCO2 levels correlates with the effect on 218 
clinical outcomes (Figure 6 a-d). These exploratory analyses suggested a trend towards a 219 
correlation between changes in hypercapnia status and hospital admissions (based on 8 220 
RCTs21;23-25;27;31-33). Such a potential correlation was not observed for mortality (based on 10 221 
RCTs19;21;23-27;31-33. Baseline hypercapnia status did not appear to predict response to NIV for 222 
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mortality (based on 10 RCTs19;21;23-27;31-33); the data was suggestive of a possible trend 223 
towards a correlation between baseline hypercapnia and hospital admissions (based on 8 224 
RCTs21;23-25;27;31-33). Formal sub-group analysis based on level of hypercapnia were however 225 
not deemed to be appropriate as this would have meant dichotomising trials based on an 226 
arbitrary CO2 threshold. Adherence to NIV and effect of NIV settings could also not be 227 
analyzed. 228 
Different types of NIV 229 
With regard to the effectiveness of different NIV settings, three small crossover trials in 230 
stable populations were identified; two38;39 comparing higher versus lower pressure NIV, and 231 
one40 comparing different back-up rates. All were short-term (6-8 weeks) and did not assess 232 
mortality or hospitalizations/exacerbations. Treatment compliance was similar between arms 233 
in two studies39;40, and higher in the high pressure arm for the third38 but drop-out rates were 234 
high in the pressure trials.38;39 The limited QOL data precluded drawing firm conclusions. The 235 
only statistically significant result 38 was greater PaCO2 reduction with higher pressure NIV 236 
(supplementary file ).  237 
 238 
DISCUSSION 239 
This is the first systematic review of domiciliary NIV to attempt to account for differing 240 
baseline risks of exacerbation by categorising populations into stable and post-hospital 241 
based on proximity to an in-patient stay for an exacerbation; it is also the most 242 
comprehensive to date, including evidence from RCTs, non-randomized controlled studies 243 
and RCTs comparing different NIV settings, and without restriction to English language only 244 
publications. Overall, the evidence from RCTs in a stable population could not demonstrate 245 
benefit for mortality from domiciliary NIV compared to usual care alone ( 7 RCTs19;21;23-27  246 
and 4 controlled studies22;28-30), although there was a trend towards fewer hospital 247 
admissions (5 RCTs21;23-25;27 and 3 controlled studies22;28;29) and, to a lesser extent, improved 248 
QOL (7 RCTs17;18;21;23;26;27;41 and 1 controlled study29) for the stable population. A survival 249 
Systematic review of domiciliary non-invasive ventilation in COPD 
 
11 
 
benefit for the post-hospital population could not be shown based on three RCTs31-33, though 250 
there was some evidence of benefit based on four (potentially biased) non-randomized 251 
controlled studies34-37. Findings for hospital admissions ( 3 RCTs31-33) were inconsistent. 252 
There was too little evidence to draw any conclusions on the potential benefits of higher 253 
pressure NIV settings.  254 
 255 
Exacerbation risk and domiciliary NIV  256 
It was hoped that sub-group analyses based on the frequency of exacerbations prior to NIV 257 
treatment would be possible, as frequent exacerbators (patients with ≥2 exacerbations/year) 258 
are a clinically relevant subgroup42,with a generally stable exacerbation frequency on other 259 
existing therapies.43 However, this was hampered by lack of reporting of this parameter.  260 
 261 
There is evidence, however, to support the use of recent hospitalization as a proxy for a 262 
higher risk of recurring exacerbation. Prior hospital admission is recognized to be the biggest 263 
driver for a further exacerbation requiring admission12, and NIV use in hospital has also been 264 
recognized as a predictor of overall exacerbation rate.44 Furthermore, recurrent type 2 265 
respiratory failure, ie respiratory failure with carbon dioxide retention, occurs in over 30%, 266 
and readmission at 1 year in 60%, of those who require NIV acutely in hospital.45 267 
Consequently stratification based on NIV started at recent hospitalization was thought a 268 
justifiable surrogate marker of exacerbation risk.  In reality there is likely to be much more of 269 
a continuum of risk, and it is further unknown what proportion of the post-hospital 270 
populations considered in the individual studies are COPD patients at the more severe end 271 
of the disease spectrum. 272 
 273 
Which patients may benefit from domiciliary NIV? 274 
The results of the review show that division of data based on potential exacerbation risk did 275 
not indicate a difference between populations in terms of mortality or hospitalizations; in fact 276 
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there was no clear evidence for benefit for either population, though there was a non-277 
significant trend towards a benefit with NIV in the stable population, for hospital admissions. 278 
The apparent similarity in hospitalization effect in our chosen subgroups is perhaps 279 
surprising given that those previously admitted are at higher risk of subsequent readmission. 280 
It is possible that the division used failed to capture other important differences within and 281 
between populations-for example the pre-treatment exacerbation rates were unknown. 282 
There was evidence of some heterogeneity between both stable and post-hospital studies, 283 
with some studies showing a significant benefit from NIV; one RCT23 in a stable population 284 
showed a statistically significant benefit from NIV for mortality (Figure 2), and one RCT for 285 
stable24 and two for post-hospital populations31;33 showed significant benefit for hospital 286 
admissions (Figure 3). Two of these RCTs23;33 used a higher hypercapnia threshold for 287 
patient inclusion (>7PaCO2); one RCT25 had a lower inclusion criterion (>6Pa CO2), though 288 
means were suggestive of higher levels. There was no detail on the inclusion threshold for 289 
the third RCT.24  290 
 291 
Elements such as blood gases, prior admissions and social support have been identified as 292 
drivers to clinical decision making regarding domiciliary NIV in COPD46, all of which may 293 
impact NIV efficacy. The non-randomized post-hospital studies22;28-30 assessing mortality 294 
(Figure 2) suggest a beneficial effect from NIV (significant pooled RR) and it is possible 295 
patient selection for NIV biased findings towards a positive response to NIV. 296 
 297 
Most populations included in studies were hypercapnic (see Table 2 for details), although the 298 
threshold used to define this varied. Post-hoc analyses undertaken across both stable and 299 
post-hospital populations suggested a trend towards a positive correlation between changes 300 
in hypercapnia and hospital admissions (but not for mortality nor correlation using pre-301 
treatment PaCO2 level). As these are exploratory analyses the results should be interpreted 302 
cautiously; the analysis used aggregate -study level- data both for baseline hypercapnia, 303 
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change in hypercapnia and for clinical outcomes, and a patient level association cannot be 304 
inferred even if there is clear biological plausibility. Further caveats relate to the fact that not 305 
all trials contributed data to these analyses and that PaCO2 change scores were mostly not 306 
adjusted for baseline differences. Nevertheless it does suggest that there should be further 307 
investigation of the association between hypercapnia and clinical outcomes, particularly with 308 
regard to the ability of the NIV to reduce PaCO2 levels. Patients hypercapnic at discharge 309 
may normalize their PaCO2 levels over time, although those who remain hypercapnic have 310 
higher mortality.47 Thus if hypercapnia (or change in hypercapnia) were a driver of NIV 311 
response and were used to select patients for treatment after an exacerbation, subsequent 312 
reassessment may be needed to determine likelihood of ongoing benefit.  313 
 314 
The current recommendation in the UK suggest that domiciliary NIV is considered on health 315 
economic grounds if a patient has had three hospital admissions with acute hypercapnic 316 
respiratory failure.48 There may be other, as yet unconfirmed, patient characteristics which 317 
influence its effectiveness. Uncertainty also remains regarding the length of time NIV may 318 
provide benefit for; there are at least two RCTs49;50 looking at the effect of discontinuing NIV, 319 
but this question was beyond the scope of this systematic review. 320 
 321 
 322 
Strengths and limitations 323 
A number of RCTs of reasonably good methodological quality were available, particularly for 324 
the stable population, and a comprehensive search strategy meant that this systematic 325 
review identified more relevant studies than previous ones, even after taking into account 326 
different search periods.  No language restrictions meant that 19% of the included studies 327 
were non-English, a substantial proportion of the overall evidence base omitted by prior 328 
reviews.8-11 This is also the first systematic review to examine patient –related outcomes and 329 
incorporate data from non-randomized studies. Furthermore, by calculating summary 330 
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measures from raw data or converting data, the number of results that could be presented in 331 
forest plots was maximized. In contrast to some previous systematic reviews, secondary 332 
outcome data (lung function, blood gases and 6MWD) were not pooled due to a lack of 333 
results adjusted for baseline differences. This means that our analyses are likely to be more 334 
robust.  335 
There were several limitations in the available data, largely due to inconsistency of reporting 336 
(particularly for hospital admissions) or measurement tools (especially for QOL). This meant 337 
that not all available evidence could contribute to the pooled estimates. Furthermore, 338 
admissions data may be skewed, thus the mean (SD) may not be an appropriate metric to 339 
use, though it was frequently reported. For primary outcomes, there was a lack of data 340 
explicitly linking the number of exacerbations to subsequent hospitalizations and survival for 341 
individual patients. This latter point has potential implications for double-counting data as 342 
these outcomes are not independent of each other. Ventilator settings may influence 343 
effectiveness, and settings have changed over time, such that earlier settings may today be 344 
considered ineffective. The small crossover trials38;3940 in this analysis did not allow any 345 
conclusions to be drawn, and sub-group analysis based on the larger/parallel trials was not 346 
possible due to inconsistent reporting: studies variously reported mean, median or target 347 
settings, based either on pressure, blood gas or volume targets, with some stating only that 348 
levels were adjusted to patient comfort/tolerance. Reporting times also varied (eg at start of 349 
study or at discharge). 350 
 351 
Recommendations for future research pertaining to domiciliary NIV in COPD 352 
Variable quality of data reporting, lack of exacerbation data, potential bias and heterogeneity 353 
of reported outcomes were striking features of the included studies. These features are not 354 
uncommonly encountered when conducting systematic reviews. Whilst trials of medications 355 
are often required to report certain outcomes as part of the licensing process, medical device 356 
studies, such as those included in our review, have not always had to meet such standards 357 
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despite also being subject to regulatory processes. More detailed reporting of exacerbations 358 
in particular would be valuable in this high risk population. It has been suggested that new 359 
RCTs could include a sham NIV arm in order to minimize potential bias, as well a higher and 360 
lower pressure NIV arm, to enable further exploration of the relationship between pressure 361 
and effectiveness; many of the earlier studies included used pressures which experts would 362 
now consider equivalent to a sham treatment (eg Casanova 200019). However, sham NIV 363 
could lead to an overestimate of the potential benefit of NIV, due to its potential disbenefits 364 
on quality-of-life, therefore two control arms (with and without sham NIV) are more likely to 365 
be appropriate. Qualitative work in NIV users and prescribers not surprisingly suggests a 366 
focus on patient-centered measures (eg QOL, daily activity) is needed, alongside research 367 
to delineate those in whom the treatment is most effective.46 Which instruments best capture 368 
QOL in this patient group and whether instruments are convertible is debatable.  369 
 370 
There is at least one ongoing trial (the UK HOT-HMV trial, NCT00990132), which includes a 371 
population with an underlying risk of recurrent events similar to the post-hospital population 372 
described here. Findings from this trial will be important, but additional evidence from 373 
individual patient data (IPD) analyses of pooled studies may be required to determine 374 
whether specific patient characteristics or equipment settings predict benefit from NIV, and 375 
to establish optimum time-points for starting (and potentially discontinuing) NIV. A previous 376 
review8;9 attempted such analyses, but based on a smaller group of studies, and without 377 
considering hospitalizations or survival. 378 
 379 
Conclusions 380 
The effectiveness of domiciliary NIV remains uncertain, however some patients appear to 381 
benefit. Further research is required to identify these patients and to explore the relevance of 382 
hypercapnic status or changes in hypercapnia due to NIV in influencing clinical outcomes for 383 
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patients on long-term NIV; optimum time-points for starting NIV and equipment settings also 384 
need to be established. 385 
 386 
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